

UCSF

UC San Francisco Previously Published Works

Title

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Permalink

<https://escholarship.org/uc/item/62b8f24h>

Journal

Cancer Discovery, 3(3)

ISSN

2159-8274

Authors

Puissant, Alexandre
Frumm, Stacey M
Alexe, Gabriela
et al.

Publication Date

2013-03-01

DOI

10.1158/2159-8290.cd-12-0418

Peer reviewed

Published in final edited form as:

Cancer Discov. 2013 March ; 3(3): 308–323. doi:10.1158/2159-8290.CD-12-0418.

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Alexandre Puissant^{1,*}, Stacey M. Frumm^{1,*}, Gabriela Alexe^{1,2,3}, Christopher F. Bassil¹, Jun Qi⁴, Yvan H. Chanthery⁵, Erin A. Nekritz⁵, Rhamy Zeid⁴, W. Clay Gustafson⁵, Patricia Greninger⁶, Matthew J. Garnett⁷, Ultan McDermott⁷, Cyril H. Benes⁶, Andrew L. Kung¹, William A. Weiss^{5,8}, James E. Bradner^{4,9}, and Kimberly Stegmaier^{1,2}

¹Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA

²The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA

³Bioinformatics Graduate Program, Boston University, Boston, Massachusetts 02215, USA

⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA

⁵Department of Pediatrics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, USA

⁶Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA

⁷Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SD, UK

⁸Department of Neurology, Neurosurgery, Brain Tumor Research Center, University of California, San Francisco, California 94158, USA

⁹Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA

Abstract

Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically-defined cancer cell lines using a prototypical inhibitor of BET bromodomains. Integration of genetic features with chemosensitivity data revealed a robust correlation between *MYCN* amplification and sensitivity to bromodomain inhibition. We characterized the mechanistic and translational significance of this finding in neuroblastoma, a childhood cancer with frequent amplification of *MYCN*. Genome-wide expression analysis demonstrated downregulation of the *MYCN* transcriptional program accompanied by suppression of *MYCN* transcription. Functionally, bromodomain-mediated inhibition of *MYCN* impaired growth and induced apoptosis in neuroblastoma. BRD4 knock-down phenocopied these effects, establishing BET bromodomains as transcriptional regulators of *MYCN*. BET inhibition conferred a significant survival advantage in three *in vivo* neuroblastoma

Correspondence: Kimberly Stegmaier, M.D., kimberly_stegmaier@dfci.harvard.edu, Phone: 617-632-4438, Fax: 617-632-4850, James E. Bradner, M.D., james_bradner@dfci.harvard.edu, Phone: 617-632-6629, Fax: 617-582-7370.

*These authors have contributed equally to this work.

Disclosures: JEB and the Dana-Farber Cancer Institute established Tensha Therapeutics to translate drug-like inhibitors of BET bromodomains as cancer therapeutic agents. All other authors have no relevant, potential conflicts-of-interest to report.

models, providing a compelling rationale for developing BET bromodomain inhibitors in patients with neuroblastoma.

Significance—Biomarkers of response to small-molecule inhibitors of BET bromodomains, a new compound class with promising anti-cancer activity, have been lacking. Here, we reveal *MYCN* amplification as a strong genetic predictor of sensitivity to BET bromodomain inhibitors, demonstrate a mechanistic rationale for this finding, and provide a translational framework for clinical trial development of BET bromodomain inhibitors for pediatric patients with *MYCN*-amplified neuroblastoma.

Keywords

BET bromodomain inhibitor; JQ1; MYCN; neuroblastoma; BRD4

Introduction

The interplay between master regulatory transcription factors and specific chromatin-associated co-activators is an emerging hallmark of cancer. Cancer genomic discovery efforts continue to reveal mutations in epigenetic modifiers, and laboratory efforts to validate functional dependencies are ongoing (1). Moreover, there are notable examples of successful commercial development of drugs targeting epigenetic modifiers, including the development of inhibitors of enzymatic “writers,” such as DNA methyltransferases for myelodysplastic syndrome, and inhibitors of enzymatic “erasers,” such as histone deacetylases for cutaneous T-cell lymphoma.

Modulation of the epigenetic regulators known as “readers” has recently emerged as a therapeutic strategy in cancer treatment. These epigenetic “readers” are structurally diverse proteins, which recognize and bind to covalent modifications of chromatin (2). One important modification associated with open chromatin and transcriptional activation is the side-chain acetylation of lysine residues on histone tails (3). The dominant mode of recognition of acetylated lysine residues is by bromodomains, present in 47 human proteins (4-6). We and others have described the therapeutic potential of targeting one bromodomain-containing family important in regulating transcription, epigenetic memory, and cell growth: the BET (bromodomain and extra-terminal domain) family, composed of BRD2, BRD3, BRD4, and BRDT. Numerous hematologic malignancies and the highly malignant solid tumor NUT midline carcinoma are responsive to BET inhibition *in vitro* and in mouse models (7-12).

While disease-specific indications for drugs modifying epigenetic regulators have been uncovered, precise genomic biomarkers predictive of treatment response remain elusive. To date, the best validated genetic predictor of response to BET inhibitors is in a rare genetically-defined subset of poorly differentiated squamous cell carcinomas (NUT midline carcinoma), where the presence of recurrent t (15;19) chromosomal translocation results in the expression of the twin N-terminal bromodomains of BRD4 as an in-frame fusion with the NUT protein (13). High-throughput pharmacogenomic profiling offers the opportunity to reveal new insights into selective responses to drugs in defined cancer genotypes. Initial efforts to connect drug response with genotype in the NCI60 cell line panel have since been expanded to screening campaigns in large panels of genetically characterized cancer cell lines (14-17). These efforts have revealed both expected and unexpected connections. For example, the anticipated response to ALK inhibitors in tumors with aberrant ALK activation, such as lymphoma, non-small cell lung cancer, and neuroblastoma, was demonstrated in a screen of over 600 tumor cell lines (15). More recently, the unexpected connections between response to poly (ADP-ribose) polymerase (PARP) inhibitors and

expression of the EWS/FLI fusion protein in Ewing sarcoma was elucidated in a screen of 130 drugs in over 600 cancer cell lines (16). In an independent study of 24 anti-cancer drugs in 479 human cancer cell lines, new connections were also observed between small-molecule sensitivities and cell lineage, gene expression, and genotype (17).

We performed a high-throughput pharmacogenomic screen to identify biomarkers of response to BET bromodomain inhibitors. The prototype ligand JQ1, a novel thienotriazolo-1,4-diazepine, which displaces BET bromodomains from chromatin by competitively binding to the acetyl lysine recognition pocket, has been validated in numerous models, nominating it as an excellent chemical probe for high-throughput screening (7-10). In this study, we therefore queried a large compendium of genetically characterized tumor cell lines to identify predictors of sensitivity to JQ1. We identified *MYCN* amplification as a top predictive marker of response to JQ1 treatment and characterized the mechanistic and translational significance of this finding in neuroblastoma, the most common extra-cranial solid tumor diagnosed in children, and a cancer notable for frequent *MYCN* amplification in patients with high-risk disease.

Results

High-throughput Pharmacogenomic Profiling Reveals *MYCN* Amplification as a Predictor of Response to Bromodomain Inhibitors

We first conducted an unbiased screen of a collection of 673 genetically characterized tumor derived cell lines (16) to understand response and resistance to BET bromodomain inhibition, so as to discover new opportunities for therapeutic development. Cell lines with response to JQ1 yielding $IC_{50} = 1 \mu M$ and $E_{max} = 70\%$ were designated as sensitive and all other were designated as resistant in a stringent classification schema. Cell lines arising from the pediatric solid tumor of neural crest origin, neuroblastoma, were identified as among the most JQ1-sensitive and *MYCN* amplification as the most predictive marker of sensitivity; four cell lines out of the 99 sensitive cell lines are *MYCN* amplified and zero lines out of the 237 resistant cell lines are *MYCN* amplified. The two-tailed Fisher exact test returns a P value of 0.007 (Fig. 1A-B and Supplementary Table S1). We next determined expression level of *MYCN* in the neuroblastoma cell lines from the primary screen (Supplementary Fig. S1A) and evaluated the correlation of *MYCN* protein levels with JQ1 response. *MYCN* protein level is also substantially correlated with response to JQ1 treatment (Fig. 1C).

We retested one of the most highly sensitive *MYCN*-amplified cell lines from the screen, BE(2)-C, and multiple additional *MYCN*-amplified neuroblastoma cell lines confirmed to have elevated levels of *MYCN* protein (Supplementary Fig. S1B). Nearly all of the *MYCN*-amplified cell lines tested responded to JQ1 and a panel of structurally distinct BET bromodomain inhibitors, each of which conferred a dose-responsive, inhibitory effect on cell viability as well as growth over time (Fig. 1D-F and Supplementary Table S2). The only exception in this cell line panel was NGP, which was comparatively insensitive to all of the BET bromodomain inhibitors tested. Importantly, cell growth was not affected in any cell lines by the (-)-JQ1 enantiomer, which lacks activity against BET bromodomains in biochemical and biological assays, further supporting an on-target mechanism of action. Similarly, we retested one of the least sensitive cell lines from the primary screen, the *MYCN*-wildtype neuroblastoma cell line SK-N-AS and a second *MYCN*-wildtype cell line SH-SY5Y not in the primary screen. As predicted, SK-N-AS was insensitive to the effects of JQ1, and SH-SY5Y was less sensitive than the *MYCN*-amplified cell lines based upon the maximal response (E_{max}) (Supplementary Fig. S2A-B and Supplementary Table S2).

JQ1 Induces Cell Cycle Arrest and Apoptosis

To further characterize the phenotypic consequences of JQ1 treatment on responsive *MYCN*-amplified neuroblastoma cells, we determined its effects on cell cycle arrest and apoptosis. JQ1 treatment induced a G0/G1 arrest and a decrease in S phase at 24 hours by flow cytometric evaluation of propidium iodide staining (Fig. 2A and Supplementary Fig. S3). There was a progressive increase in cell death, based on the increase in the subG1 fraction, with marked induction of apoptosis confirmed by annexin V staining at 72 hours (Fig. 2B). In contrast, the effect of JQ1 on cell cycle and apoptosis in *MYCN*-wildtype neuroblastoma was less pronounced (Supplementary Fig. S4A and B).

Bromodomain Inhibition Downregulates MYCN and c-MYC Transcriptional Programs in Neuroblastoma

Prior research from our laboratory has demonstrated a selective effect of BET bromodomain inhibition on the expression and function of c-MYC in hematologic malignancies (8-10). We thus hypothesized that the selective sensitivity of neuroblastoma lines to BET inhibition may relate to impaired function of the *MYCN* and c-MYC transcriptional activators. We profiled two of the highly sensitive neuroblastoma cell lines, BE(2)-C and Kelly, treated with 1 μ M JQ1 for 24 hours using genome-wide transcriptional profiling coupled with gene set enrichment analysis (GSEA) (18). The top 50 differentially upregulated and downregulated genes are depicted in the heatmap in Fig. 3A and the full list is reported in Supplementary Table S3. Consistent with the established biological role of BET co-activators in chromatin-dependent transcriptional activation, there was a preponderance of downregulated genes in comparison to upregulated genes. Acute JQ1 treatment prompted a dynamic change in transcription, with 122 genes significantly upregulated and 193 genes significantly downregulated based on permutation $P < 0.05$ and FDR < 0.05 for signal-to-noise in the comparison of all vehicle-treated versus all JQ1-treated samples. To assess the effects of JQ1 more specifically on transcriptional programs regulated by either *MYCN* or c-MYC, we interrogated the data with published, validated gene signatures for statistically significant enrichment by GSEA. GSEA seeks to estimate the significance of over-representation of an independently defined set of genes (e.g., c-MYC or *MYCN* pathways) in the highly correlated or anti-correlated genes in the gene expression data set. The majority of the *MYCN* and c-MYC-related gene sets were statistically enriched among genes downregulated by BET bromodomain inhibition in neuroblastoma (Fig. 3B and C). Because the *MYCN* signature in the Molecular Signature Database (MSigDB) was derived in small cell lung cancer cells (19), we sought to develop a custom *MYCN* upregulated signature in neuroblastoma cells utilizing a publicly available data set of primary neuroblastoma tumors characterized for *MYCN* amplification status (20). This *MYCN* signature was also highly downregulated by JQ1 treatment of neuroblastoma cell lines based on GSEA (Fig. 3D and Supplementary Table S4). An open-ended enrichment analysis was next performed, as a measure of specificity, on the entire set of transcription factor target gene signatures available from MSigDB (21). In almost all cases, gene sets defined by adjacency to MYC-binding motifs (both *MYCN* and c-MYC) were highly enriched in genes whose expression is suppressed by JQ1 in neuroblastoma (Fig. 3E).

Recently, we reported the unexpected downregulation of *MYC* expression in multiple myeloma and acute leukemia models by BET bromodomain inhibitors (8-10). Localization of BRD4 to strong enhancer elements proximal to *MYC* prompted the consideration that expression of amplified *MYCN* may, indeed, be dependent on BET bromodomains. We therefore evaluated the effects of JQ1 treatment on *MYCN* expression. While not in the top 100 differentially expressed genes, *MYCN* expression was significantly downregulated in the genome-wide expression profiling of both neuroblastoma cell lines for three of the four PrimeView representative probes with an average reduction of 50% (Supplementary Table

S5). These results were confirmed in the three neuroblastoma cell lines responsive to JQ1 (BE(2)-C, Kelly, and LAN-1) by RT-PCR and immunoblot (Fig. 3F and G). In contrast, *MYCN* expression was not downregulated in the cell line most insensitive to JQ1, NGP. Finally, c-MYC expression level was reduced in response to JQ1 treatment across all the *MYCN* amplified or non amplified neuroblastoma cell lines (Supplementary Fig. S5). Taken together, these data provide strong evidence that the MYCN program is downregulated in neuroblastoma cell lines by JQ1 treatment and, as observed for *MYC* in several hematologic disease models, BET bromodomain inhibition targets the expression of *MYCN* itself.

Context-Independent and Dependent Transcriptional Effects of BET Bromodomain Inhibition in Cancer Cells

While the transcriptional programs altered by BET bromodomain inhibition in individual diseases have been established, an integrated analysis has not yet been performed. To establish neuroblastoma-specific and canonical BET bromodomain-dependent transcriptional pathways, we analyzed three data sets profiling the transcriptional changes associated with JQ1 treatment in cancer cell lines (multiple myeloma (8), AML (9), and neuroblastoma) to determine whether there is a robust, cell context independent JQ1 signature. First, we generated signatures of genes whose expression is regulated (up and down) by JQ1 treatment in neuroblastoma and used this as a gene set to query both the multiple myeloma and the AML transcriptional profiling data sets. There was significant enrichment of these neuroblastoma JQ1 signatures in the hematopoietic malignancies with an FDR < 0.25 (Supplementary Fig. S6A).

Next, we developed hematopoietic malignancy signatures for both upregulated and downregulated genes with JQ1 treatment using the multiple myeloma and the AML data sets. We applied these signatures as gene sets to query our neuroblastoma transcriptional profiling data by GSEA. Both of these signatures were consistently enriched in the expected directions in neuroblastoma cell lines treated with JQ1 (Supplementary Fig. S6B). Moreover, all of the JQ1 signatures were enriched in the treatment of AML cells with a structurally distinct BET bromodomain inhibitor, I-BET151 (11), consistent with an on-target effect of JQ1 (Supplementary Fig. S7). Finally, we developed a consensus signature across all three data sets (Fig. 4A) and determined the relevance to primary human neuroblastoma. The consensus JQ1 signature was significantly associated with *MYCN*-amplified neuroblastoma when projected into a primary human neuroblastoma gene expression profiling data set with annotation for *MYCN* status and stage, suggesting that the signature has relevance beyond cancer cell lines grown in culture to *bona fide* human disease (Fig. 4B). We next determined the biological and functional connections among those genes. Notably, while many individual gene sets were significant, there was marked enrichment for multiple gene sets associated with MYCN and c-MYC, E2F, cell cycle, transcription/translation, metabolism and DNA damage/repair (Fig. 4C and Supplementary Table S6). Taken together, this analysis suggests that there is indeed a consensus transcriptional signature altered by JQ1 treatment of cancer cells with c-MYC and MYCN gene sets, and their associated biological functions, serving as hubs.

While BET bromodomain inhibition alters a common transcriptional program across structurally distinct compounds and cancers of different lineages, we were also interested in the transcriptional changes unique to *MYCN*-amplified neuroblastoma. In this case, we identified a set of genes whose expression is uniquely altered in neuroblastoma but not in the hematopoietic cancer cell lines (Supplementary Fig. S8). Here, there was evidence of loss of lineage related genes with JQ1 treatment, reflected in the downregulation of gene sets associated with neural crest stem cells and neurotransmitter release, as well as the downregulation of sets of genes with proximal promoter regions containing binding sites for LHX3 (LIM homeobox 3, a gene involved in neural development) and of ZIC3 (zinc finger

protein of the cerebellum 3) (Fig. 4D and E) (22). In addition, consistent with the observed phenotypic consequences of the compound in neuroblastoma cells, there was enrichment for gene sets associated with apoptosis (Fig. 4F). A full list of enriched gene sets is presented in Supplementary Table S7.

A BET Bromodomain Inhibitor Displaces BRD4 from the MYCN Promoter Region and MYCN Targets Are Downregulated

It was previously shown that BET bromodomain Inhibitors displace BRD4 from the *c-MYC* promoter region suggesting the hypothesis that BET inhibitors would similarly displace BRD4 from the *MYCN* promoter region (8). Using chromatin immunoprecipitation (ChIP) PCR, we observed BRD4 localization to the *MYCN* promoter, as well as a putative enhancer region. JQ1 treatment resulted in displacement of the BRD4 co-activator protein from both elements, providing a mechanistic explanation for the observed JQ1-dependent decrease in *MYCN* transcription in sensitive neuroblastoma cells (Fig. 5A). Moreover, with JQ1 treatment two well-reported targets of *MYCN*, *MCM7* and *MDM2*, are confirmed to be downregulated by western blotting, and expression of the neuroblastoma specific target identified in our expression profiling analysis, *PHOX2B*, is also downregulated (Fig 5B and C). As expected, there is no alteration of these targets in NGP, where JQ1 treatment does not lead to downregulation of *MYCN* expression.

BRD4 Suppression by shRNA Recapitulates the Effects of JQ1 Treatment in Neuroblastoma Cell Lines

Previous studies have focused on the role of a specific BET family member, BRD4, which is potently inhibited by JQ1 and implicated in several malignancies, including NUT midline carcinoma, AML, B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (7-9). Moreover, a recent siRNA screen to identify synthetic lethal interactions with *MYC* overexpression revealed BRD4 as a candidate gene (23). Therefore, we studied selective suppression of BRD4 by shRNA in the three JQ1-sensitive neuroblastoma cell lines. Four shRNAs directed against BRD4 were evaluated and demonstrated to alter relative cell viability and growth over a six day time course, with a dose response in all three lines sensitive to JQ1 (Fig. 6A and B). As seen with JQ1 treatment, there was a striking induction of apoptosis (Fig. 6C) and downregulation of *MYCN* expression by RT-PCR and immunoblot with the top three shRNAs in the three JQ1 sensitive cell lines (Fig. 6D and E). Moreover, as expected, direct suppression of *MYCN* by shRNA resulted in growth arrest and apoptotic cell death (Supplementary Fig. S9A-C). However, in the JQ1 resistant neuroblastoma cell line NGP, BRD4-directed shRNAs did not alter growth/viability, induce apoptosis or lead to suppression of *MYCN* expression (Fig. 6A-E). Accordingly to these results, BRD4 knock-down did not significantly diminish growth of two *MYCN* non amplified cell lines, SH-SY5Y and SK-N-AS (Supplementary Fig. S10A-B).

Efficacy of JQ1 Treatment in Independent Murine Models of Neuroblastoma

Because there is no consensus regarding the most relevant *in vivo* mouse model for preclinical testing of a new therapy, we performed *in vivo* testing of JQ1 in three unique models of *MYCN*-amplified neuroblastoma: a subcutaneous xenograft, an orthotopic primary human xenograft, and an experimentally-derived mouse model of *MYCN*-amplified neuroblastoma (24). First, JQ1 was evaluated in a BE(2)-C cell line xenograft model established by subcutaneous injection into NOD-SCID-IL2R γ^{null} (NSG) mice. Tumor-bearing mice were treated with 50 mg/kg of JQ1 or vehicle delivered by daily intraperitoneal injection (n = 10 per group) until sacrifice. JQ1 treatment significantly diminished tumor volume and prolonged overall survival compared to control-treated mice without an effect on body weight (Fig. 7A and B and Supplementary Fig. S11A) and no overt toxicities were observed. In contrast, treatment of the *MYCN*-wildtype SH-SY5Y subcutaneous xenograft

with JQ1 did not significantly prolong survival or reduce tumor volume (Supplementary Fig. S11B and C).

In the primary human orthotopic xenograft model, a human *MYCN*-amplified primary neuroblastoma tumor was obtained from a heavily-pretreated child with relapsed metastatic and drug-resistant disease. Tumor pieces were implanted into the kidney capsule of nude mice, and the mice were treated once daily with 50 mg/kg of JQ1 intraperitoneally for 28 days, starting seven days after orthotopic transplantation. As shown in Figure 7C, JQ1 treatment significantly prolonged survival compared to vehicle treatment.

Finally, we tested the effects of JQ1 therapy in a genetically engineered mouse model (GEMM) of *MYCN*-amplified neuroblastoma (TH-*MYCN*) (24). TH-*MYCN* mice with palpable tumors were treated with JQ1 or vehicle, as above, once daily for 28 days. A marked improvement in survival for JQ1-treated mice was observed (Fig. 7D). Tumor biopsies were obtained on therapy with JQ1 or vehicle and assessed for pharmacodynamic effects. As shown in Figure 7E, JQ1 conferred an inhibitory effect on cellular proliferation evidenced by Ki67 staining, an increase in apoptosis by cleaved caspase 3 staining, and an inhibitory effect on the expression of *MYCN* itself and its downstream target MCM7 (Fig. 7F).

Discussion

Neuroblastoma, a tumor arising from primitive neural crest cells in the sympathetic nervous system, is the most common extra-cranial solid tumor in children (25). While progress has been substantial for treating patients with low-risk disease, the majority of children with neuroblastoma present with high-risk disease, and many of these children will succumb to neuroblastoma despite intensive chemotherapy with autologous stem cell transplantation, surgery and radiation (26). New treatment approaches are clearly needed for these patients as the delivery of dose-intensified, cytotoxic chemotherapy is already maximized. The pathologic activation of *MYCN* plays a central role in high-risk neuroblastoma, with *MYCN* amplification identified in 25% of primary neuroblastoma tumors and nearly half of high-risk cases (26-29). Genomic studies of neuroblastoma tumors, including massively parallel sequencing, have failed to reveal other recurrent and imminently targetable molecular lesions, with the exception of mutations in anaplastic lymphoma receptor kinase (*ALK*) in neuroblastomas which often co-harbor *MYCN* amplification (20, 30-34). The central role of the *MYCN* oncogene in neuroblastoma tumorigenesis, and its limited expression in mature, normal tissues, make it a compelling target for drug development. While transcription factor oncoproteins have largely been refractory to conventional drug discovery approaches, the selective targeting of JQ1 in neuroblastoma raises the possibility of targeting *MYCN* by bromodomain inhibitors in this disease. Indeed, our data also supports the use of other BET bromodomain inhibitors, expanding the possibilities for future clinical testing.

While numerous examples now exist of genotypic predictors of chemical phenotypes, particularly for kinase inhibitors (35-37), we are still lacking genetic/genomic predictors of response to most drugs in current clinical use and in early clinical testing. In this study, we reveal the power of large-scale screening of highly annotated collections of cancer cell lines to uncover a strong genetic predictor of response to BET bromodomain inhibitors. Many of the cancer cell lines in our high-throughput screening study, particularly among the solid tumors, were insensitive to JQ1, suggesting that JQ1 is not a general cytotoxic agent. While nearly all of the prior literature supports the use of BET bromodomain inhibitors in hematologic malignancies, our work demonstrates a strong indication for the use of BET bromodomain inhibitors in a genetically defined solid tumor, *MYCN*-amplified neuroblastoma. Similar to the observation that *MYC* is transcriptionally regulated by

bromodomain inhibitors, we demonstrated that *MYCN* expression is repressed both by JQ1 treatment and by shRNA directed against BRD4. Importantly, in the one *MYCN* amplified cell line (NGP) with no response to JQ1 or other structurally distinct BET bromodomain inhibitors, no downregulation of *MYCN* expression at either a transcriptional or protein level occurred with either JQ1 treatment or BRD4-directed shRNA. While the precise mechanism for the failure to suppress *MYCN* expression in NGP by BET bromodomain inhibition is still under investigation, these data support the assessment of *MYCN* downregulation as a putative approach to response stratification in clinical trials investigating this compound class. Furthermore, while in primary human neuroblastoma tumors, *MYCN* amplification is strongly correlated with the JQ1 expression signature derived from cell lines, there are some primary human tumors which cluster with the JQ1 signature but lack *MYCN* amplification, suggesting that additional predictors of response to JQ1 remain to be discovered.

In addition to identifying a consensus JQ1 gene expression signature shared by JQ1-responsive cell lines, we also identified a gene signature uniquely regulated in neuroblastoma, including genes associated with neural cellular identity. For example, one of the genes whose expression is uniquely modulated by BET bromodomain inhibition in neuroblastoma is *PHOX2B*, a gene encoding a transcription factor involved in the differentiation of neural crest cells. *PHOX2B* is mutated in neuroblastoma, particularly in association with familial neuroblastoma and with congenital central hypoventilation syndrome and Hirschprung's disease (38-40). Similarly, tyrosine hydroxylase expression is uniquely modulated by BET bromodomain inhibition with JQ1 in neuroblastoma, a likely explanation for the downregulation of *MYCN* expression in our GEMM model of neuroblastoma in which *MYCN* is driven from a tyrosine hydroxylase promoter. The even more dramatic effects of JQ1 on the downstream target of *MYCN*, *MCM7*, could be explained by the contribution of a direct inhibitory effect of JQ1 on the interaction of BRD4 and *MYCN* at *MYCN* promoter sites.

While it will be important in future studies to extend testing of BET bromodomain inhibition to other diseases with *MYCN* amplification, such as medulloblastoma (41), the open-source nature of publicly available screening data infinitely expands the utility of any individual laboratory's screening efforts by enabling re-mining of the data. For example, if we relax the criteria for identifying candidate biomarkers of sensitivity versus resistance to JQ1 to significant ($P < 0.05$) values for Fisher's exact test at the twenty-fifth percentile (sensitivity) or the seventy fifth percentile (resistance) of the $\text{Ln}(\text{IC}_{50})$ distribution, *NOTCH1* activation is also correlated with response to JQ1, nominating diseases with aberrant *NOTCH1* activation, such as T-cell acute lymphoblastic leukemia (T-ALL) (42) and chronic lymphocytic leukemia (CLL) (43), for future study (Supplementary Table S8). Similarly, expression of *GNAS*, *MDM2*, and *NF2* should be explored as predictors of resistance and the combination of *MDM2* inhibitors with bromodomain inhibitors tested. Moreover, the recent report that *ALK(F1174L)/MYCN* tumors exhibit increased *MYCN* dosage due to *ALK(F1174L)*-induced activation of the PI3K/AKT/mTOR and MAPK pathways suggests the possibility of combining *ALK* inhibitors with BET bromodomain inhibitors in neuroblastoma (44).

In summary, we have leveraged high-throughput, cell-based screening of genetically characterized cancer cell lines to identify *MYCN* amplification as a strong predictor of sensitivity to BET bromodomain inhibition. We have confirmed this finding in *MYCN*-amplified neuroblastoma and executed on the preclinical validation of this hypothesis. With a survival advantage observed in three independent *in vivo* models of neuroblastoma treated with JQ1, including a highly chemotherapy-resistant genetically engineered *MYCN* mouse

model, the clinical development of bromodomain inhibitors for testing in children with relapsed/refractory neuroblastoma is already underway.

Methods

Genomic Characterization of Cancer Cell Lines

A total of 84 of the most frequently mutated, amplified, deleted or rearranged cancer genes were examined in the cell line collection. 65 genes were sequenced to base-pair resolution across all coding exons for each gene by capillary sequencing. The presence of seven of the most commonly rearranged cancer genes (e.g. BCR-ABL and EWS-FLI1) was determined across the drug screen cell line panel by the design of breakpoint-specific sequence primers that enabled the detection of the rearrangement following capillary sequencing. In addition, analysis of microsatellite instability (MSI) was carried out according to the guidelines set down by “The International Workshop on Microsatellite Instability and RER Phenotypes in Cancer Detection and Familial Predisposition” workshop (45). Samples were screened using the markers BAT25, BAT26, D5S346, D2S123 and D17S250 and were characterized as MSI if two or more markers showed instability. Total integral copy number values across the footprints of the cancer genes were determined from Affymetrix SNP6.0 microarray data using the ‘PICNIC’ algorithm to predict copy number segments in each of the cell lines (46). For a gene to be classified as amplified, the entire coding sequence must be contained in one contiguous segment defined by PICNIC, and have a total copy number of eight or more. Deletions must occur within a single contiguous segment with copy number zero. A complete description of the characterization of the cancer cell lines collection used in this study is available from the Cancer Genome Project webpages (47).

Cell Line Screening

Cell lines in an exponential phase of growth were seeded at optimal density previously determined to provide maximum signal in control (untreated) wells, while maintaining growth through the experimental exposure. Cells were seeded on Day 1, with drug delivered the following day. Nine concentrations of (+)-JQ1 were applied to cells at a step-wise two-fold dilution series. After 72 hours of drug exposure, cells were fixed and stained with Syto60 (Invitrogen) for fluorescence measurement as described previously (48). Replicate experiments were variably performed for quality assessment during the screening phase. Stringent quality control criteria were applied and estimates of IC_{50} were derived from the 9-dose response curves as described previously (16). Drug response is presented as the $LN[IC_{50}]$ plotted against the E_{max} (the maximum effect corresponding to the minimum measured viability). Enrichment for a given organ of origin (673 cell lines) or genotype (473 cell lines with genotype information) in the sensitive cell lines was tested using a Fisher exact test based approach. Cell lines with response to JQ1 yielding $IC_{50} < 1 \mu M$ and $E_{max} > 70\%$ were designated as sensitive and all other were designated as resistant in the most stringent classification schema. Using less stringent criteria, cell lines were assigned to the sensitive or resistant group thresholds corresponding to the fifth to the seventy fifth percentile of the distribution of $LN(IC_{50})$ values. A Fisher exact test was used to determine the statistical enrichment of a given genotype (or organ) in the sensitive or resistant group at each threshold. In this analysis mutation is defined as either the presence of a specific gene fusion, a sequence change or a copy number change across 84 cancer genes.

Cell Culture

Neuroblastoma cell lines were maintained in DMEM (Cellgro, Manassas, VA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin-streptomycin with glutamine (Cellgro). BE(2)-C and SH-SY5Y were obtained from the American Type Culture Collection, and Kelly, LAN-1, SK-N-AS and NGP were

kindly provided by Dr. Rani George. The identity of all lines was verified by small tandem repeat profiling performed by the Shannon McCormack Advanced Molecular Diagnostics Laboratory at the Dana-Farber Cancer Institute (Boston, MA, USA).

Compounds, Cellular Viability, and Growth

JQ1R, JQ1S, I-BET and I-BET151 were synthesized by Dr. Jun Qi. For the testing of multiple BET bromodomain inhibitors in four neuroblastoma cell lines, cells were seeded onto 384-well tissue culture-treated plates at a density of 2000 cells/well in a volume of 50 μ L/well. Addition of inhibitor was performed with a JANUS Workstation (Perkin Elmer, Waltham, MA) using a 384-well pinhead tool that is calibrated to deliver 100 nL drug/well. After 72 hours of incubation with inhibitor, cells were analyzed for cell viability using the ATPlite (Perkin Elmer, Waltham MA) luminescent assay kit per the manufacturer's instructions using ATP content as a surrogate for viable cell number. Luminescence was read on an EnVision 2104 Multilabel Plate Reader (Perkin Elmer, Waltham, MA). Nonlinear dose response curves were fitted to the data using Graphpad Prism software (La Jolla, CA). To assess growth, neuroblastoma cell lines were incubated with JQ1 in 384-well plates. ATP content was measured on days zero, two, three, and five using CellTiter Glo (Promega, Madison, WI, USA) per the manufacturer's instructions.

Flow Cytometry

Cell cycle was determined by measuring DNA content using propidium iodide staining. Apoptosis was measured using the Annexin V: FITC Apoptosis Detection Kit as per the manufacturer's protocol (BD Pharmingen, San Jose, CA, USA).

Protein Extraction and Immunoblotting

Protein was extracted from cells by lysis with Cell Signaling Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA) containing Complete, EDTA-free Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany) and PhosSTOP Phosphatase Inhibitor (Roche Diagnostics). Immunoblots were run as previously described (49). Primary antibodies included anti-MYCN (Abcam 16898), anti-BRD4 (Abcam 75898), anti-Vinculin (Abcam 18058), anti-MCM7 (Cell Signaling Technology #4018S), anti-MDM2 (Santa Cruz Biotechnology sc-813) and anti-Actin (Neomarkers MS1295P).

RNA Extraction and Real-time RT-PCR

RNA was extracted from cells with the RNeasy Kit and on-column DNA digestion (Qiagen, Valencia, CA, USA). Primers and probes for *MYCN* (Hs00232074_m1), *BRD4* (Hs04188087_m1), *PHOX2B* (Hs00243679_m1) and the control gene *RPL13A* (Hs01926559_g1) were obtained from Applied Biosystems (Carlsbad, CA, USA). Data were collected in technical quadruplicate, analyzed using the $\Delta\Delta$ CT method, and plotted as percentage of transcript compared to the negative control condition.

shRNA Studies

Virus was created by transfecting 293T cells with packaging plasmid (pCMV-d8.9), envelope plasmid (VSV-G), and a pLK0.1 hairpin plasmid (see Supplementary Table S9 for hairpin target sequences) using Fugene 6 per the manufacturer's instructions (Promega). It was filtered with a 0.4 μ M filter before use. Neuroblastoma cell lines were transduced in 10 cm plates with 2 mL virus and 8 μ g/ml polybrene (Sigma-Aldrich) for 2 hours at 37°C, and then 8 mL medium was added to each plate. On day two post-transduction, 2 μ g/mL (BE(2)-C) or 1 μ g/ml (all other cell lines) puromycin (Sigma-Aldrich) was added to select for infected cells and four days post-transduction, experiments to evaluate cell growth, apoptosis, and protein and transcript levels were begun.

Genome-wide Expression Analysis

BE(2)-C and Kelly cells were treated in triplicate with 1 μ M JQ1 or DMSO for 24 hours. RNA was extracted and a decrease in *MYCN* transcript was confirmed by real time RT-PCR as described above. The samples were profiled using the Affymetrix PrimeView Human Gene Expression Array (Affymetrix) at Beth Israel Deaconess Medical Center (Boston, MA, USA). The computational analysis pipeline was performed on the Genome Space bioinformatics platform (50).

Data Processing—The CEL data files were subjected to quality control and passed tests based on distance between arrays, array intensity distribution and variance mean dependence which are implemented in the *ArrayQuality* R package (Bioconductor). The raw expression data was processed and log₂ transformed by applying the RMA algorithm in the *Affymetrix* package (Bioconductor). All probe sets with an average log₂ expression below four were considered under-expressed and were designated as “filtered”. Of the 49,293 probe sets on the Affymetrix PrimeView Human Gene Expression Array, 45,925 probe sets remained after filtering. The data from the 45,925 probe sets was further collapsed to 19,108 non-redundant genes with distinct HUGO symbols, by assigning to each gene the probe set with the maximum average expression intensity. Gene expression data is available from Gene Expression Omnibus Expression (GEO) (accession no. [XXX]).

Comparative Marker Analysis—The 12 samples available in the data were separated into two groups: 1 μ M JQ1-treated samples versus DMSO-treated samples. The Comparative Marker Selection module from GenePattern 3.5.0 (50) was employed to identify individual genes differentially expressed between the JQ1- and the DMSO-treated groups (51). A 2-sided signal-to-noise ratio (SNR) test followed by 1000 permutations of phenotype labels was performed for this analysis. The settings for the SNR parameters were *log-transformed-data:yes, complete:no, balanced:no, smooth p-values:yes*. A permutation $P < 0.05$, a Benjamini-Hochberg false discovery rate (FDR) < 0.05 , accounting for multiple hypothesis testing, and an absolute fold change (FC) ≥ 2 served as a cutoff for significant genes. Heatmaps were created with GENE-E software (50).

Gene Set Enrichment Analysis—The GSEA software (50) was utilized to identify pathways, or groups of functionally related genes, deregulated by the JQ1 treatment (18). The goal of GSEA is to identify groups of genes sharing common biological function (genesets), which are distributed at the top or at the bottom of the ranked list of differentially expressed genes. GSEA assigns to each gene set an enrichment score (ES) calculated as a running sum statistic by walking down the ranked list of differentially expressed genes, increasing the sum when encountering genes in the gene set and decreasing it when encountering genes not in the gene set. The significance of the ES is estimated based on a permutation p-value and adjusted for multiple hypotheses testing through FDR. The set of differentially expressed genes accounting for the enrichment signal is called the leading edge.

GSEA was run on the collections of 3272 curated gene sets (c2) and 615 transcription factor targets (c3) from version 3.1 of the Molecular Signatures Database (50). Gene sets with less than 15 genes or more than 500 genes were excluded from the analysis. Gene sets with an FDR < 0.25 and a nominal $P < 0.05$ were considered significant. The gene ranking metric in the weighted ES was the 2-sided SNR, and the p-values were calculated using 1,000 permutations of the phenotype.

MYCN Amplification Signature—A gene expression upregulation signature to distinguish primary neuroblastoma tumors with *MYCN* amplification from those without

MYCN amplification was created from the expression profiling of primary neuroblastoma tumors (GSE12460, available at the GEO Database) (20). The signature was generated based on the Comparative Marker Selection algorithm of GenePattern with the cutoff threshold 2 for the absolute fold change ratio and the cutoff 0.05 for the p-value and the FDR.

A Consensus JQ1 Signature—A consensus JQ1 signature was created by intersecting the JQ1 differential expression signature in this study with those from the studies by Delmore *et al.* in multiple myeloma and Zuber *et al.* in AML (8, 9). This consensus JQ1 signature consisted of 36 genes significantly downregulated and 17 genes significantly upregulated based on the cutoffs of an absolute FC ≥ 2 , and p-value and FDR ≤ 0.05 . The consensus JQ1 signature was evaluated on the primary neuroblastoma tumor data of Janoueix-Lerosey *et al.* (20) describing stage and *MYCN* amplification status. The primary tumor data were projected onto the consensus JQ1 signature and clustered based on the average linkage hierarchical method. The JQ1 consensus signature separated the tumors into two clusters. The association of the tumor clusters with the *MYCN* status and stage was computed based on the two tailed exact Fisher test.

A relaxed consensus JQ1 signature for downregulated genes identified based on the absolute FC ≥ 1.5 and a p-value and FDR ≤ 0.05 was used in a Functional Enrichment Analysis of the consensus JQ1 signature by GSEA. Functional enrichment analysis results were visualized with Enrichment Map software and functional clusters are listed in Supplementary Table S7.

Neuroblastoma JQ1-specific Signature—A collection of 116 genes significantly downregulated (absolute FC ≥ 2 , and p-value and FDR ≤ 0.05) in the JQ1-treated neuroblastoma cell lines vs. control, and unchanged in any of the other two JQ1-treated studies, was identified. The small size of the neuroblastoma JQ1 specific signature, even in a relaxed format, necessitated the use of a Fisher test rather than GSEA to identify the functional relatedness of these genes.

Chromatin Immunoprecipitation (ChIP)

ChIP studies were carried out as described previously using specific primers for the *MYCN* locus (8). Primers were designed to amplify two sites within the promoter region (5'-3') and a negative control region outside the promoter region: *MYCN* promoter site 1 (forward) TTTGCACCTTCGGACTACCC and (reverse) TTTGACTGCGTGTGTGTCAG; *MYCN* promoter site 2 (forward) TCCTGGGAAGTGTGTTGGAG and (reverse) TCCTCGGATGGCTACAGTCT; *MYCN* negative region (forward) GTATCACCGTCCATTCCCCG and (reverse) TTGGAGGCAGCTCAAAGACC. Enrichment data were analyzed by calculating the immunoprecipitated DNA percentage of input DNA for each sample (triplicate PCR reactions).

In Vivo Studies

Cell line xenograft tumors were established by implanting 2 million BE(2)-C-LucNeo cells or 2 million SH-SY5Y cells in 30% Matrigel (BD Biosciences) subcutaneously in the flanks of 6 week old female NOD-SCID-IL2R γ^{null} (NSG) mice (Jackson Labs). Serial bioluminescence imaging was performed after injection with 75 mg/kg of D-luciferin (Promega) using a Xenogen IVIS Spectrum instrument (PerkinElmer). Eight days after tumor inoculation, mice with established tumors defined as increasing bioluminescence and measurable tumor volume were divided into cohorts to be treated with 50 mg/kg JQ1 or vehicle (10% DMSO in 5% dextrose) delivered by daily intraperitoneal injection (n=10 per group). Because of rapid tumor growth and saturation, bioluminescence imaging was

abandoned as an endpoint. Tumor volume was determined using the equation $\text{volume} = 0.5 \times \text{length} \times \text{width}^2$. Mice were sacrificed when tumors reached 2 cm in the longest linear dimension. Statistical significance was determined by log-rank (Mantel-Cox) test for survival curves. This study was conducted using protocols approved by the Dana-Farber Cancer Institute Animal Care and Use Committee.

TH-MYC*N* mice with palpable tumors (mean age at detection was 60 +/- 15d) were treated with JQ1 via intraperitoneal injection (50 mg/kg in 1:10 solution of DMSO:10% cyclodextrin) or vehicle (1:10 solution of DMSO:10% cyclodextrin), once daily for 28 days (n=5 per group). In the primary human orthotopic model, a human *MYC*N**-amplified primary neuroblastoma tumor was obtained from a child with relapsed, drug-resistant metastatic disease (SFNB-06). Tumor pieces (4mm³) were implanted into kidney capsule of nude mice and maintained as a continuous xenograft. Human primary SFNB-06 mice were treated once daily for 28 days, starting 7 days after orthotopic transplantation, (dosage as above) (n=5 per group). Statistical significance was determined by log-rank (Mantel-Cox) test for survival curves. All mice were monitored until euthanasia was required, in accordance with the University of California, San Francisco, institutional IACUC guidelines.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Rani George for providing cell lines and Ronald Paranal for technical support.

Grant Support: V Foundation for Cancer Research Translational Grant (KS and JEB), Friends for Life Fellowship (KS and ALK), Howard Hughes Medical Institute Physician-Scientist Early Career Award (KS), Damon-Runyon Cancer Research Foundation and Smith Family Foundation (JEB and JQ), Alex's Lemonade Stand (WCG), NIH grants R01CA102321 (WAW), P01CA081403 (WAW), K08NS079485 (WCG), and T32CA151022 (YHC); The Wellcome Trust (086357; UM, MJG, PG, CHB); The Katie Dougherty Foundation (WAW), The Cancer League, Inc (WAW), and the Samuel Waxman Cancer Research Foundation (JEB and WAW), L'Association pour la Recherche sur le Cancer (AP). KS is also supported by a Stand-Up-to-Cancer Innovative Research Grant, a program of the Entertainment Industry Foundation (SU2C-AACR-IRG0509).

References

1. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. *Nat Rev Cancer*. 2011; 11:726–34. [PubMed: 21941284]
2. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. *Nature structural & molecular biology*. 2007; 14:1025–40.
3. Marushige K. Activation of chromatin by acetylation of histone side chains. *Proc Natl Acad Sci U S A*. 1976; 73:3937–41. [PubMed: 1069278]
4. Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. *FEBS letters*. 2002; 513:124–8. [PubMed: 11911891]
5. Dey A, Nishiyama A, Karpova T, McNally J, Ozato K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. *Molecular biology of the cell*. 2009; 20:4899–909. [PubMed: 19812244]
6. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. *Cell*. 2012; 149:214–31. [PubMed: 22464331]
7. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. *Nature*. 2010; 471:235–9.

8. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell*. 2011; 146:904–17. [PubMed: 21889194]
9. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature*. 2011; 478:524–8. [PubMed: 21814200]
10. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-MYC and IL7R in high-risk acute lymphoblastic leukemia. *Blood*. 2012
11. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. *Nature*. 2011; 478:529–33. [PubMed: 21964340]
12. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. *Proc Natl Acad Sci U S A*. 2011; 108:16669–74. [PubMed: 21949397]
13. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. *Cancer Res*. 2003; 63:304–7. [PubMed: 12543779]
14. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, et al. An information-intensive approach to the molecular pharmacology of cancer. *Science*. 1997; 275:343–9. [PubMed: 8994024]
15. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. *Cancer Res*. 2008; 68:3389–95. [PubMed: 18451166]
16. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature*. 2012; 483:570–5. [PubMed: 22460902]
17. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*. 2012; 483:603–7. [PubMed: 22460905]
18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005; 102:15545–50. [PubMed: 16199517]
19. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. *Oncogene*. 2006; 25:130–8. [PubMed: 16116477]
20. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. *Nature*. 2008; 455:967–70. [PubMed: 18923523]
21. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. *Bioinformatics*. 2011; 27:1739–40. [PubMed: 21546393]
22. Thor S, Andersson SG, Tomlinson A, Thomas JB. A LIM-homeodomain combinatorial code for motor-neuron pathway selection. *Nature*. 1999; 397:76–80. [PubMed: 9892357]
23. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. *Proc Natl Acad Sci U S A*. 2012; 109:9545–50. [PubMed: 22623531]
24. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. *EMBO J*. 1997; 16:2985–95. [PubMed: 9214616]
25. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Database. 2008. Available at <http://seercancer.gov>
26. Maris JM. Recent advances in neuroblastoma. *N Engl J Med*. 2010; 362:2202–11. [PubMed: 20558371]
27. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. *Nature*. 1983; 305:245–8. [PubMed: 6888561]

28. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. *N Engl J Med*. 1985; 313:1111–6. [PubMed: 4047115]
29. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. *Science*. 1984; 224:1121–4. [PubMed: 6719137]
30. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neurogenesis genes. *Nature*. 2012; 483:589–93. [PubMed: 22367537]
31. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. *JAMA*. 2012; 307:1062–71. [PubMed: 22416102]
32. George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. *Nature*. 2008; 455:975–8. [PubMed: 18923525]
33. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature*. 2008; 455:930–5. [PubMed: 18724359]
34. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. *Nature*. 2008; 455:971–4. [PubMed: 18923524]
35. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*. 2001; 344:1031–7. [PubMed: 11287972]
36. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med*. 2010; 363:809–19. [PubMed: 20818844]
37. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*. 2010; 363:1693–703. [PubMed: 20979469]
38. Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, de Pontual L, Schleiermacher G, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. *Am J Hum Genet*. 2004; 74:761–4. [PubMed: 15024693]
39. Raabe EH, Laudenslager M, Winter C, Wasserman N, Cole K, LaQuaglia M, et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. *Oncogene*. 2008; 27:469–76. [PubMed: 17637745]
40. van Limpt V, Schramm A, van Lakeman A, Sluis P, Chan A, van Noesel M, et al. The Phox2B homeobox gene is mutated in sporadic neuroblastomas. *Oncogene*. 2004; 23:9280–8. [PubMed: 15516980]
41. Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. *J Clin Oncol*. 2010; 28:3054–60. [PubMed: 20479417]
42. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science*. 2004; 306:269–71. [PubMed: 15472075]
43. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature*. 2011; 475:101–5. [PubMed: 21642962]
44. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, et al. The ALK(F1174L) Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. *Cancer Cell*. 2012; 22:117–30. [PubMed: 22789543]
45. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res*. 1998; 58:5248–57. [PubMed: 9823339]

46. Greenman CD, Bignell G, Butler A, Edkins S, Hinton J, Beare D, et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. *Biostatistics*. 2010; 11:164–75. [PubMed: 19837654]
47. Characterization of the cancer cell lines collection available from the Cancer Genome Project webpages. <http://www.sanger.ac.uk/genetics/CGP/CellLines/>
48. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. *Proc Natl Acad Sci U S A*. 2007; 104:19936–41. [PubMed: 18077425]
49. Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, et al. The intersection of genetic and chemical genomic screens identifies GSK-3alpha as a target in human acute myeloid leukemia. *J Clin Invest*. 2012; 122:935–47. [PubMed: 22326953]
50. GENE-E version 1, GenePattern version 3.5.0, GSEA version 1.3, Cytoscape version 2.8.3 and MSigDB version 3.1. Available from <http://www.genomespace.org>
51. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. *Nat Genet*. 2006; 38:500–1. [PubMed: 16642009]




Figure 1. *MYCN*-amplified neuroblastoma is sensitive to the effects of BET bromodomain inhibition. (A) Anti-proliferative activity of JQ1 was profiled in over 650 cancer cell lines, revealing a broad range of sensitivity and resistance. Red dots are neuroblastoma cell lines with *MYCN* amplification based on SNP 6.0 arrays and/or high levels of protein expression. Black dots indicate neuroblastoma cell lines wildtype for *MYCN* and poor *MYCN* expression. Drug response is presented as the natural log of the half-maximal effective concentration [$\text{Ln}(IC_{50})$], plotted against the maximum effect corresponding to the minimum measured viability (E_{max}). (B) Distribution of E_{max} and $\text{Ln}(IC_{50})$ for *MYCN* wildtype versus *MYCN* amplified cancer cell lines based on SNP 6.0 copy number analysis. P value

calculated using non parametric Mann-Whitney test. Red squares indicate *MYCN*-amplified neuroblastoma cell lines. (C) Spearman correlation between minimum measured viability (E_{max}) and the expression level of *MYCN* normalized by Actin level (ratio *MYCN*/Actin). (D) Structures of BET bromodomain inhibitors. (+)-JQ1, I-BET, and I-BET151 are all active, structurally distinct, BET bromodomain inhibitors. JQ1R is the inactive (–)-JQ1 enantiomer. (E) Dose response of neuroblastoma cell line viability with BET bromodomain inhibitor treatment measured by a luminescent ATP detection assay. Data represent mean \pm SEM of four biological replicates. (F) Four *MYCN*-amplified neuroblastoma cell lines were used to determine the effects of JQ1 on growth. Values over time are shown relative to the day zero values, with error bars representing the mean \pm SD of eight replicates per condition.




Figure 2. JQ1 treatment induces a G0/G1 arrest and apoptosis in neuroblastoma cell lines. Indicated neuroblastoma cell lines were treated with 1 μ M JQ1 for (A) 24, 48 and 72 hours before cell cycle analysis or (B) 72 hours before measuring apoptosis by annexin V staining detected by flow cytometry.




Figure 3. Inhibition of MYCN and c-MYC-dependent transcription by JQ1 treatment of neuroblastoma cells. (A) Heatmap of the top 50 down- and upregulated genes following 24 hours of 1 μ M JQ1 treatment of neuroblastoma cell lines based on an SNR Score and $P < 0.05$. Data are presented row normalized. (B) GSEA demonstrating downregulation of MYCN and c-MYC-dependent gene sets and representative sets of genes with proximal promoter regions containing MYCN or MYC-MAX binding sites in the transcriptional profiles of neuroblastoma cell lines treated with JQ1. Depicted is the plot of the running sum for the molecular signature data base (MSigDB) gene set within the JQ1 neuroblastoma dataset including the maximum enrichment score and the leading edge subset of enriched

genes. (C) Table of selective gene sets enriched among genes downregulated by JQ1 in neuroblastoma cell lines based on GSEA (size = number of genes in each set, NES = normalized enrichment score, and FDR = false discovery rate). (D) GSEA showing downregulation of a custom MYCN gene set derived from the comparison of *MYCN*-amplified versus *MYCN*-non-amplified primary neuroblastoma tumors. (E) Quantitative comparison of all transcription factor target gene sets available from the MSigDB by GSEA for downregulation in JQ1-treated neuroblastoma cells. Data are presented as a scatterplot of FDR versus NES for each evaluated gene set. Red indicates sets for either MYCN or c-MYC and gray for other transcription factors. (F) Neuroblastoma cell lines were treated with 1 μ M JQ1 or DMSO for 8 hours. After RNA extraction, level of MYCN transcript was quantified. Expression values are shown relative to the DMSO condition for each cell line. Error bars represent mean \pm SD of four technical replicates. * $P < 0.001$ calculated using a one-way ANOVA with Bonferroni correction comparing JQ1 treatment to DMSO within a cell line. (G) Western-blot for MYCN on whole cell extracts from four neuroblastoma cell lines treated with 1 μ M JQ1 or DMSO for 24 hours.





Figure 4. Transcriptional changes associated with BET bromodomain inhibition by JQ1. (A) Heatmap of the 36 down- and 17 up-regulated genes after JQ1 treatment with a consistent direction of regulation in neuroblastoma, multiple myeloma, and AML and fold-change greater than two and $P < 0.05$. Data are presented row normalized. (B) Heatmap of the JQ1 consensus signature developed in Fig 4A evaluated in a data set profiling genome-wide expression of primary neuroblastoma tumors. JQ1 consensus signature genes denoted in blue are downregulated and those in red are upregulated with JQ1 treatment. Data are presented row normalized. The neuroblastoma samples cluster into two groups which are associated with the *MYCN* amplification status of the tumors ($P < 0.002$ by Fisher exact test) and with high

stage (stage 3 and 4) versus low stage (all other) ($P < 0.002$ by Fisher exact test). (C) A relaxed consensus JQ1 downregulation signature was identified based on the absolute FC 1.5 and P -value and FDR = 0.05 and was interrogated in a Functional Enrichment Analysis across the MSigDB. The results were visualized with the Enrichment Map software which organizes the significant gene sets into a network called an “enrichment map.” In the enrichment map the nodes correspond to gene sets and the edges reflect significant overlap between the nodes according to a Fisher test. The hubs correspond to collections of genes sets with a unifying class label according to GO biological processes. The size of the nodes is correlated with the number of genes in the gene set. (D) Table describing the results of Fisher tests for the MSigDB signatures enriched with genes selectively downregulated by JQ1 in neuroblastoma cells. Heatmap of the genes uniquely regulated by JQ1 in neuroblastoma in the neural development (E) and apoptosis-related (F) gene sets. Data are presented row normalized.

**Figure 5.**

(A) ChIP with a BRD4 antibody at two sites within the *MYCN* promoter region in BE(2)-C cells treated with 1 μ M JQ1 for 24 hours. Enrichment is shown as the percentage of total input DNA. The negative control region primers amplify within a gene desert region ~1Mb away from *MYCN*. Error bars represent \pm SEM of triplicate data. * $P < 0.05$, ** $P < 0.01$ (paired t-test). (B) Western blot demonstrating effects of 1 μ M JQ1 treatment for 24 hours on the expression of *MCM7* and *MDM2* in *MYCN*-amplified neuroblastoma cells. (C) Neuroblastoma cell lines were treated with 1 μ M JQ1 or DMSO for 24 hours. After RNA extraction, level of *PHOX2B* transcript was quantified. Expression values are shown relative to the DMSO condition for each cell line. Error bars represent mean \pm SD of four

technical replicates. * $P < 0.001$ calculated using a one-way ANOVA with Bonferroni correction comparing JQ1 treatment to DMSO within a cell line.




Figure 6. Effect of BRD4 downregulation on neuroblastoma cell lines. (A-E) The three most JQ1-sensitive neuroblastoma cell lines were transduced with shRNAs targeting BRD4 or a control shRNA. (A) RNA was extracted at day three post-transduction and BRD4 transcript level was quantified. Shown are the expression values relative to the shRNA control-transduced cells. Error bars represent mean \pm SD of four technical replicates. * P < 0.05 and ** P < 0.01 calculated using a one-way ANOVA, with Bonferroni correction. (B) Viability values over days post-transduction are shown relative to the day zero (time of seeding) values, with errors bars representing the mean \pm SD of eight replicates per condition. (C) Apoptosis analysis was performed on day 6 post-transduction. (D) Western blots showing BRD4 and MYCN protein levels on day four post-transduction with three BRD4-directed shRNAs. (E) MYCN transcript levels were quantified four days after transduction. The expression values are relative to cells infected with a control shRNA. Error bars represents mean \pm SD of four technical replicates. * P < 0.001 calculated using a

one-way ANOVA, with Bonferroni correction, comparing each BRD4-directed shRNA to the control shRNA within a cell line.




Figure 7.

Testing of JQ1 in multiple *in vivo* models of *MYCN*-amplified neuroblastoma. (A) Mice were injected with BE(2)-C subcutaneously and treated with JQ1 or vehicle once tumors reached 100 mm³. After 15 days, tumor volume was measured. Error bars indicate mean \pm SD of five mice. $*P=0.01$ calculated using non parametric Mann-Whitney test. (B) Effects of JQ1 treatment on survival in the BE(2)-C xenograft model. Day 0 indicates the first day of treatment and mice were treated until time of sacrifice. (C) A human *MYCN*-amplified primary neuroblastoma tumor was implanted into kidney capsule of nude mice and mice were treated once daily with JQ1 for 28 days, starting 7 days after orthotopic transplantation. (D) TH-*MYCN* mice with palpable tumors were treated with JQ1 or vehicle once daily for

28 days. Statistical significance (A-C) was determined by log-rank (Mantel-Cox) test for the survival curves as shown. Day 0 indicates the day of treatment initiation. (E) Staining for Ki-67 (red), cleaved caspase 3 (green) and DAPI (blue) in GEMM tumors treated with either vehicle or JQ1 as indicated. (F) Western blot indicating the expression of MYCN and MCM7 in GEMM tumors treated with either vehicle or JQ1 as indicated.